Blinatumomab + Standard of Care Chemotherapy
Phase 3Terminated 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
Conditions
Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
Trial Timeline
Jan 3, 2014 → Mar 14, 2017
NCT ID
NCT02013167About Blinatumomab + Standard of Care Chemotherapy
Blinatumomab + Standard of Care Chemotherapy is a phase 3 stage product being developed by Amgen for Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia. The current trial status is terminated. This product is registered under clinical trial identifier NCT02013167. Target conditions include Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia.
What happened to similar drugs?
0 of 9 similar drugs in Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia were approved
Approved (0) Terminated (0) Active (9)
🔄SHR2554; Chidamide analog tablets + SHR2554 analog tablets; ChidamideJiangsu Hengrui MedicinePhase 3
🔄Axicabtagene Ciloleucel + Platinum-containing Salvage Chemotherapy + Cyclophosphamide + FludarabineGilead SciencesPhase 3
Hype Score Breakdown
Clinical
17
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02013167 | Phase 3 | Terminated |
Competing Products
20 competing products in Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia